Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ionis Pharmaceuticals Inc (IONS)  
$28.40 0.05 (0.18%) as of 4:30 Thu 4/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 158,000,000
Market Cap: 4.49(B)
Last Volume: 998,037 Avg Vol: 989,714
52 Week Range: $25.51 - $51.86
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 7.9
Insider 3/6 Months : 8.5
Guru Rank Number :  162
Guru Rank Value     : 8.6
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ionis Pharmaceuticals is engaged in RNA-targeted therapeuty. Co.'s commercial products are SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA injection for intrathecal use is a survival motor neuron-2 directed antisense medicine indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI injection is an RNA-targeted medicine indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 5,000 5,000 5,000
Total Buy Value $0 $181,079 $181,079 $181,079
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 1 1
Total Shares Sold 75,734 188,361 227,132 766,650
Total Sell Value $2,389,680 $6,188,124 $7,920,890 $34,714,285
Total People Sold 10 12 15 17
Total Sell Transactions 14 29 37 96
End Date 2025-01-19 2024-10-18 2024-04-19 2023-04-20

   
Records found: 1050
  Page 1 of 42  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Jenne Kyle EVP, Chf GL Pdt Str Ofcr   •       –      –    2025-04-16 4 S $28.36 $85,534 D/D (3,016) 11,199 -0%     
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2025-04-16 4 S $28.37 $19,292 D/D (680) 56,660 -0%     
   Baroldi Joseph EVP, Chief Business Officer   •       –      –    2025-04-16 4 S $28.40 $111,555 D/D (3,928) 31,926 -0%     
   Jenne Kyle EVP, Chf GL Pdt Str Ofcr   •       –      –    2025-04-15 4 OE $0.00 $0 D/D 12,226 14,215     -
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2025-04-15 4 OE $0.00 $0 D/D 1,875 57,340     -
   Baroldi Joseph EVP, Chief Business Officer   •       –      –    2025-04-15 4 OE $0.00 $0 D/D 10,837 35,854     -
   Monia Brett P Chief Executive Officer   •       •      –    2025-03-11 4 AS $32.32 $4,525 D/D (140) 180,980 -16%     
   Monia Brett P Chief Executive Officer   •       •      –    2025-02-28 4 A $28.21 $12,328 D/D 437 181,120     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-02-28 4 A $28.21 $15,629 D/D 554 56,799     -
   Geary Richard S EVP, Chief Development Officer   •       –      –    2025-02-28 4 A $28.21 $11,708 D/D 415 99,492     -
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2025-02-28 4 A $28.21 $9,028 D/D 320 93,466     -
   Swayze Eric EVP Research   •       –      –    2025-02-28 4 A $28.21 $11,708 D/D 415 48,432     -
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2025-02-28 4 A $28.21 $11,680 D/D 414 55,465     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-02-20 4 AS $32.35 $39,046 D/D (1,207) 56,245 -15%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-02-04 4 AS $31.62 $194,939 D/D (6,165) 57,452 -12%     
   Monia Brett P Chief Executive Officer   •       •      –    2025-02-04 4 AS $31.65 $1,229,463 D/D (38,843) 180,683 -12%     
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2025-01-31 4 S $32.46 $43,079 D/D (1,327) 93,146 11%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2025-01-31 4 S $32.20 $47,780 D/D (1,484) 61,056 11%     
   Swayze Eric EVP Research   •       –      –    2025-01-31 4 S $32.31 $44,162 D/D (1,367) 48,017 11%     
   Monia Brett P Chief Executive Officer   •       •      –    2025-01-31 4 S $32.45 $429,655 D/D (13,242) 219,526 11%     
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2025-01-31 4 S $32.44 $49,404 D/D (1,523) 110,500 11%     
   Geary Richard S EVP, Chief Development Officer   •       –      –    2025-01-31 4 S $32.40 $45,561 D/D (1,406) 99,077 11%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-01-31 4 S $32.49 $45,685 D/D (1,406) 63,617 11%     
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2025-01-30 4 A $0.00 $0 D/D 3,607 94,473     -
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2025-01-30 4 A $0.00 $0 D/D 4,032 62,540     -
  1050 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 42
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us